| Literature DB >> 31295423 |
Leila S Ross1, David A Fidock2.
Abstract
Intensified treatment and control efforts since the early 2000s have dramatically reduced the burden of Plasmodium falciparum <span class="Disease">malaria. However, drug resistance threatens to derail this progress. In this review, we present four antimalarial resistance case studies that differ in timeline, technical approaches, mechanisms of action, and categories of resistance: chloroquine, sulfadoxine-pyrimethamine, artemisinin, and piperaquine. Lessons learned from prior losses of treatment efficacy, drug combinations, and control strategies will help advance mechanistic research into how P. falciparum parasites acquire resistance to current first-line artemisinin-based combination therapies. Understanding resistance in the clinic and laboratory is essential to prolong the effectiveness of current antimalarial drugs and to optimize the pipeline of future medicines.Entities:
Keywords: Plasmodium; antimalarials; artemisinin; drug resistance; genetics; genomics; malaria; mutations
Mesh:
Substances:
Year: 2019 PMID: 31295423 PMCID: PMC6639022 DOI: 10.1016/j.chom.2019.06.001
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 21.023